A NanoGuard Vaginal Matrix as a Dual-Protection Contraceptive Microbicide

NanoGuard 阴道基质作为双重保护避孕杀菌剂

基本信息

  • 批准号:
    8499242
  • 负责人:
  • 金额:
    $ 18.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The dual impacts of the HIV/AIDS pandemic and unintended pregnancies constitute a major health burden for women worldwide. As a consequence, dual protection technologies (DPT) combining safe, effective, and easily reversible options for contraception with a topical microbicide against sexual HIV-1 transmission are a global health priority. However, there is currently no clinically approved female-controlled dual protection technology to prevent sexual HIV-1 transmission and unintended pregnancies. A bottleneck for developing effective DPTs against HIV and unintended pregnancies is in the integration of multiple design criteria into a single device. We hypothesize that patterned electrospun nanofibers impregnated with agents that have specific action against HIV and sperm, and are designed to protect both the cervix and vagina, will provide a chemical and physical barrier for dual-prevention of sexual HIV transmission and pregnancy. We propose a paradigm shift from the development of existing DPTs by using biodegradable nanofibers for vaginal drug delivery that achieve the following specific aims: (1) Electrospin nanofibers for concomitant and sustained release of different chemical classes of agents (small molecule drug and biologics); (2) Fabricate three-dimensional electrospun nanofibers with controlled architecture, mechanical strength, and mucoadhesive properties; (3) measure effect of genital secretions and erosion on the release kinetics and activity of the nanofiber contraceptive microbicide; (4) measure biodistribution and anti-HIV activity of nanofibers in tissue explants; and (5) measure biodistribution and contraceptive activity of nanofibers in a mouse model. The success of this proposal is through integrating research on biomaterials synthesis and characterization, HIV microbicide development and efficacy testing, and non-hormonal contraceptive development and efficacy testing. This novel vaginal drug delivery platform could potentially be used for prevention of other sexually-transmitted or reproductive tract infections alone and in combination, intravaginal delivery of nanoparticles, or be designed for rectal drug delivery.
描述(由申请人提供):艾滋病毒/艾滋病流行和意外怀孕的双重影响构成了全世界妇女的主要健康负担。因此,双重保护技术 (DPT) 将安全、有效且易于逆转的避孕方案与针对性 HIV-1 传播的外用杀菌剂相结合,成为全球卫生优先事项。然而,目前尚无临床批准的女性控制双重保护技术来预防 HIV-1 性传播和意外怀孕。开发针对艾滋病毒和意外怀孕的有效 DPT 的一个瓶颈是将多种设计标准集成到单个设备中。我们假设,图案化的电纺纳米纤维浸有对艾滋病毒和精子具有特异性作用的试剂,旨在保护子宫颈和阴道,将为艾滋病毒性传播和怀孕的双重预防提供化学和物理屏障。我们建议通过使用可生物降解的纳米纤维进行阴道药物输送来改变现有 DPT 的发展范式,以实现以下具体目标:(1)静电纺丝纳米纤维用于不同化学类别药物(小分子药物和生物制剂)的伴随和持续释放; (2) 制备具有可控结构、机械强度和粘膜粘附性能的三维静电纺丝纳米纤维; (3)测量生殖器分泌物和侵蚀对纳米纤维避孕杀菌剂的释放动力学和活性的影响; (4)测量组织外植体中纳米纤维的生物分布和抗HIV活性; (5) 在小鼠模型中测量纳米纤维的生物分布和避孕活性。该提案的成功在于整合了生物材料合成和表征、艾滋病毒杀微生物剂开发和功效测试以及非激素避孕药开发和功效测试方面的研究。这种新型阴道药物递送平台有可能单独或组合用于预防其他性传播或生殖道感染,阴道内递送纳米颗粒,或设计用于直肠药物递送。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kim A. Woodrow其他文献

Compositions et procédés pour une administration contrôlée d'acides ribonucléiques inhibiteurs
控制酸核糖核酸抑制剂给药的组合物和方法
  • DOI:
  • 发表时间:
    2009
  • 期刊:
  • 影响因子:
    0
  • 作者:
    W. M. Saltzman;Kim A. Woodrow
  • 通讯作者:
    Kim A. Woodrow
Dissolving microneedles for nucleic acid delivery: A systematic search, review, and data synthesis
用于核酸递送的溶解微针:系统搜索、综述和数据综合
  • DOI:
    10.1016/j.actbio.2025.05.025
  • 发表时间:
    2025-06-15
  • 期刊:
  • 影响因子:
    9.600
  • 作者:
    Carmen I. Tobos;Kim A. Woodrow
  • 通讯作者:
    Kim A. Woodrow
Prodrug approaches for the development of a long-acting drug delivery systems
用于开发长效药物递送系统的前药方法
  • DOI:
    10.1016/j.addr.2023.114860
  • 发表时间:
    2023-07-01
  • 期刊:
  • 影响因子:
    17.600
  • 作者:
    Shin-Tian Chien;Ian T. Suydam;Kim A. Woodrow
  • 通讯作者:
    Kim A. Woodrow

Kim A. Woodrow的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kim A. Woodrow', 18)}}的其他基金

Drug-eluting fibers for on-demand and extended protection against HIV
药物洗脱纤维可按需提供长期的 HIV 保护
  • 批准号:
    10359034
  • 财政年份:
    2019
  • 资助金额:
    $ 18.34万
  • 项目类别:
Drug-eluting fibers for on-demand and extended protection against HIV
药物洗脱纤维可按需提供长期的 HIV 保护
  • 批准号:
    10092098
  • 财政年份:
    2019
  • 资助金额:
    $ 18.34万
  • 项目类别:
Drug-eluting fibers for on-demand and extended protection against HIV
药物洗脱纤维可按需提供长期的 HIV 保护
  • 批准号:
    9898318
  • 财政年份:
    2019
  • 资助金额:
    $ 18.34万
  • 项目类别:
Drug-eluting fibers for on-demand and extended protection against HIV
药物洗脱纤维可按需提供长期的 HIV 保护
  • 批准号:
    10576394
  • 财政年份:
    2019
  • 资助金额:
    $ 18.34万
  • 项目类别:
Combination HIV prevention in drug-eluting fibers: designing for efficacy and use
药物洗脱纤维中的艾滋病毒联合预防:针对功效和用途进行设计
  • 批准号:
    9022395
  • 财政年份:
    2014
  • 资助金额:
    $ 18.34万
  • 项目类别:
Combination HIV prevention in drug-eluting fibers: designing for efficacy and use
药物洗脱纤维中的艾滋病毒联合预防:针对功效和用途进行设计
  • 批准号:
    8710724
  • 财政年份:
    2014
  • 资助金额:
    $ 18.34万
  • 项目类别:
A NanoGuard Vaginal Matrix as a Dual-Protection Contraceptive Microbicide
NanoGuard 阴道基质作为双重保护避孕杀菌剂
  • 批准号:
    8264681
  • 财政年份:
    2012
  • 资助金额:
    $ 18.34万
  • 项目类别:
Nanomaterials for engineering protection in the genital mucosa
用于生殖粘膜工程保护的纳米材料
  • 批准号:
    8355391
  • 财政年份:
    2012
  • 资助金额:
    $ 18.34万
  • 项目类别:
Nanoparticle microbicides for delivery of combination antiretroviral drugs
用于递送组合抗逆转录病毒药物的纳米颗粒杀微生物剂
  • 批准号:
    8676646
  • 财政年份:
    2011
  • 资助金额:
    $ 18.34万
  • 项目类别:
Nanoparticle microbicides for delivery of combination antiretroviral drugs
用于递送组合抗逆转录病毒药物的纳米颗粒杀微生物剂
  • 批准号:
    8110094
  • 财政年份:
    2011
  • 资助金额:
    $ 18.34万
  • 项目类别:

相似海外基金

Development of anti-HIV agents with dual mechanisms of actions based on triterpenoids as drug discovery templates
以三萜类化合物为药物发现模板,开发具有双重作用机制的抗 HIV 药物
  • 批准号:
    15K07998
  • 财政年份:
    2015
  • 资助金额:
    $ 18.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of anti-HIV agents targeting weak points of viral replication mechanism
针对病毒复制机制的弱点开发抗HIV药物
  • 批准号:
    26670053
  • 财政年份:
    2014
  • 资助金额:
    $ 18.34万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Structure activity and structure property relationships for novel anti-HIV agents
新型抗HIV药物的结构活性和结构性质关系
  • 批准号:
    8466077
  • 财政年份:
    2012
  • 资助金额:
    $ 18.34万
  • 项目类别:
Structure activity and structure property relationships for novel anti-HIV agents
新型抗HIV药物的结构活性和结构性质关系
  • 批准号:
    8777085
  • 财政年份:
    2012
  • 资助金额:
    $ 18.34万
  • 项目类别:
Development of anti-HIV agents that exert synergism with host immune pressure
开发与宿主免疫压力发挥协同作用的抗HIV药物
  • 批准号:
    24390254
  • 财政年份:
    2012
  • 资助金额:
    $ 18.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Design and synthesis of anti-HIV agents that inhibit the Pr55Gag membrane localization
抑制 Pr55Gag 膜定位的抗 HIV 药物的设计和合成
  • 批准号:
    24790124
  • 财政年份:
    2012
  • 资助金额:
    $ 18.34万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Structure activity and structure property relationships for novel anti-HIV agents
新型抗HIV药物的结构活性和结构性质关系
  • 批准号:
    8588784
  • 财政年份:
    2012
  • 资助金额:
    $ 18.34万
  • 项目类别:
Developing host defense peptides as novel anti-HIV agents
开发宿主防御肽作为新型抗 HIV 药物
  • 批准号:
    230278
  • 财政年份:
    2011
  • 资助金额:
    $ 18.34万
  • 项目类别:
    Fellowship Programs
Design and synthesis of anti-HIV agents that inhibit the Vif-mediated proteasome degradation of APOBEC3G
设计和合成抑制 Vif 介导的 APOBEC3G 蛋白酶体降解的抗 HIV 药物
  • 批准号:
    22659024
  • 财政年份:
    2010
  • 资助金额:
    $ 18.34万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Development of anti-HIV agents using chemical genomics based on viral self-regulation mechanism
基于病毒自我调节机制的化学基因组学抗HIV药物的开发
  • 批准号:
    22659021
  • 财政年份:
    2010
  • 资助金额:
    $ 18.34万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了